Key Points
- Director Bart Filius bought 150,000 shares of ProQR Therapeutics at $1.54 each, a transaction worth $231,000. The purchase left him with 150,000 shares total, marking a major increase in his position.
- ProQR Therapeutics recently reported quarterly EPS of -$0.15, matching analyst expectations, but revenue of $2.35 million fell short of estimates. The company also continues to post weak profitability metrics, including a negative net margin and return on equity.
- Wall Street sentiment is mixed but leans positive, with a consensus Moderate Buy rating and average price target of $7.33. Several analysts maintain buy/outperform ratings, though a few recent downgrades have tempered optimism.
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) Director Bart Filius bought 150,000 shares of the firm's stock in a transaction on Friday, June 26th. The stock was purchased at an average price of $1.54 per share, with a total value of $231,000.00. Following the transaction, the director owned 150,000 shares in the company, valued at $231,000. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
ProQR Therapeutics Price Performance
Shares of ProQR Therapeutics stock opened at $1.86 on Wednesday. ProQR Therapeutics N.V. has a 1-year low of $1.33 and a 1-year high of $3.10. The business's fifty day moving average price is $1.60 and its two-hundred day moving average price is $1.70. The company has a market capitalization of $195.97 million, a P/E ratio of -3.72 and a beta of 0.07.
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting analysts' consensus estimates of ($0.15). ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%.The company had revenue of $2.35 million for the quarter, compared to analyst estimates of $5.19 million. On average, research analysts expect that ProQR Therapeutics N.V. will post -0.57 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. raised its position in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 4,500 shares in the last quarter. Guggenheim Capital LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $35,000. Moody Lynn & Lieberson LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $50,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $51,000. Finally, Axiom Investment Management LLC acquired a new position in shares of ProQR Therapeutics in the 1st quarter worth approximately $53,000. 32.65% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the stock. Citigroup restated a "market outperform" rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Thursday, March 12th. They issued an "outperform" rating and a $9.00 price objective for the company. Wall Street Zen lowered shares of ProQR Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Saturday, May 16th. Chardan Capital dropped their target price on ProQR Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a report on Friday, June 26th. Finally, Weiss Ratings downgraded ProQR Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, June 23rd. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.33.
Get Our Latest Stock Analysis on ProQR Therapeutics
About ProQR Therapeutics
(
Get Free Report)
ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.
Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
